A citation-based method for searching scientific literature

Noopur Raje, Jesus Berdeja, Yi Lin, David Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Ashley Turka, Lyh-Ping Lam, Richard A Morgan, Kevin Friedman, Monica Massaro, Julie Wang, Greg Russotti, Zhihong Yang, Timothy Campbell, Kristen Hege, Fabio Petrocca, M Travis Quigley, Nikhil Munshi, James N Kochenderfer. N Engl J Med 2019
Times Cited: 617







List of co-cited articles
884 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R Verneris, Heather E Stefanski, Gary D Myers,[...]. N Engl J Med 2018
33

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Jennifer N Brudno, Irina Maric, Steven D Hartman, Jeremy J Rose, Michael Wang, Norris Lam, Maryalice Stetler-Stevenson, Dalia Salem, Constance Yuan, Steven Pavletic,[...]. J Clin Oncol 2018
351
33

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Adam D Cohen, Alfred L Garfall, Edward A Stadtmauer, J Joseph Melenhorst, Simon F Lacey, Eric Lancaster, Dan T Vogl, Brendan M Weiss, Karen Dengel, Annemarie Nelson,[...]. J Clin Invest 2019
288
32

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
30

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Nikhil C Munshi, Larry D Anderson, Nina Shah, Deepu Madduri, Jesús Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David Siegel, Albert Oriol,[...]. N Engl J Med 2021
221
29

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Jie Xu, Li-Juan Chen, Shuang-Shuang Yang, Yan Sun, Wen Wu, Yuan-Fang Liu, Ji Xu, Yan Zhuang, Wu Zhang, Xiang-Qin Weng,[...]. Proc Natl Acad Sci U S A 2019
157
25

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
24

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
Syed Abbas Ali, Victoria Shi, Irina Maric, Michael Wang, David F Stroncek, Jeremy J Rose, Jennifer N Brudno, Maryalice Stetler-Stevenson, Steven A Feldman, Brenna G Hansen,[...]. Blood 2016
451
23

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Wan-Hong Zhao, Jie Liu, Bai-Yan Wang, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei,[...]. J Hematol Oncol 2018
233
23

Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude, Noelle Frey, Pamela A Shaw, Richard Aplenc, David M Barrett, Nancy J Bunin, Anne Chew, Vanessa E Gonzalez, Zhaohui Zheng, Simon F Lacey,[...]. N Engl J Med 2014
20

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
Jae H Park, Isabelle Rivière, Mithat Gonen, Xiuyan Wang, Brigitte Sénéchal, Kevin J Curran, Craig Sauter, Yongzeng Wang, Bianca Santomasso, Elena Mead,[...]. N Engl J Med 2018
19

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Zhiling Yan, Jiang Cao, Hai Cheng, Jianlin Qiao, Huanxin Zhang, Ying Wang, Ming Shi, Jianping Lan, Xiaoming Fei, Lai Jin,[...]. Lancet Haematol 2019
132
18

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Daniel W Lee, Bianca D Santomasso, Frederick L Locke, Armin Ghobadi, Cameron J Turtle, Jennifer N Brudno, Marcela V Maus, Jae H Park, Elena Mead, Steven Pavletic,[...]. Biol Blood Marrow Transplant 2019
779
17

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Shaji Kumar, Bruno Paiva, Kenneth C Anderson, Brian Durie, Ola Landgren, Philippe Moreau, Nikhil Munshi, Sagar Lonial, Joan Bladé, Maria-Victoria Mateos,[...]. Lancet Oncol 2016
17

Current concepts in the diagnosis and management of cytokine release syndrome.
Daniel W Lee, Rebecca Gardner, David L Porter, Chrystal U Louis, Nabil Ahmed, Michael Jensen, Stephan A Grupp, Crystal L Mackall. Blood 2014
16

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn,[...]. N Engl J Med 2020
402
16

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, A Keith Stewart, Parameswaran Hari, Myo Htut, Alexander Lesokhin,[...]. Lancet 2021
70
22

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Robert O Carpenter, Moses O Evbuomwan, Stefania Pittaluga, Jeremy J Rose, Mark Raffeld, Shicheng Yang, Ronald E Gress, Frances T Hakim, James N Kochenderfer. Clin Cancer Res 2013
362
15

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Sattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, William Wierda, Cristina Gutierrez, Frederick L Locke, Krishna V Komanduri, Yi Lin, Nitin Jain, Naval Daver,[...]. Nat Rev Clin Oncol 2018
984
15

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J Fry, Nirali N Shah, Rimas J Orentas, Maryalice Stetler-Stevenson, Constance M Yuan, Sneha Ramakrishna, Pamela Wolters, Staci Martin, Cindy Delbrook, Bonnie Yates,[...]. Nat Med 2018
637
13

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, Yongzhi K Cui, Cindy Delbrook, Steven A Feldman, Terry J Fry, Rimas Orentas, Marianna Sabatino, Nirali N Shah,[...]. Lancet 2015
13

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Nikoletta Lendvai, Douglas Sborov,[...]. Lancet Oncol 2020
246
13

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis,[...]. Lancet 2020
324
13

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Adrienne H Long, Waleed M Haso, Jack F Shern, Kelsey M Wanhainen, Meera Murgai, Maria Ingaramo, Jillian P Smith, Alec J Walker, M Eric Kohler, Vikas R Venkateshwara,[...]. Nat Med 2015
787
12

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Stephen J Schuster, Jakub Svoboda, Elise A Chong, Sunita D Nasta, Anthony R Mato, Özlem Anak, Jennifer L Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel Landsburg,[...]. N Engl J Med 2017
878
12

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
David L Porter, Wei-Ting Hwang, Noelle V Frey, Simon F Lacey, Pamela A Shaw, Alison W Loren, Adam Bagg, Katherine T Marcucci, Angela Shen, Vanessa Gonzalez,[...]. Sci Transl Med 2015
12

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
Margot J Pont, Tyler Hill, Gabriel O Cole, Joe J Abbott, Jessica Kelliher, Alexander I Salter, Michael Hudecek, Melissa L Comstock, Anusha Rajan, Bharvin K R Patel,[...]. Blood 2019
105
12

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
747
12

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Joseph A Fraietta, Simon F Lacey, Elena J Orlando, Iulian Pruteanu-Malinici, Mercy Gohil, Stefan Lundh, Alina C Boesteanu, Yan Wang, Roddy S O'Connor, Wei-Ting Hwang,[...]. Nat Med 2018
601
12

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
Cameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Theodore A Gooley, Sindhu Cherian, Michael Hudecek, Daniel Sommermeyer, Katherine Melville, Barbara Pender, Tanya M Budiarto,[...]. J Clin Invest 2016
11

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
Richard A Morgan, James C Yang, Mio Kitano, Mark E Dudley, Carolyn M Laurencot, Steven A Rosenberg. Mol Ther 2010
11

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Ujjawal H Gandhi, Robert F Cornell, Arjun Lakshman, Zhubin J Gahvari, Elizabeth McGehee, Megan H Jagosky, Ridhi Gupta, William Varnado, Mark A Fiala, Saurabh Chhabra,[...]. Leukemia 2019
169
11

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
Michael C Milone, Jonathan D Fish, Carmine Carpenito, Richard G Carroll, Gwendolyn K Binder, David Teachey, Minu Samanta, Mehdi Lakhal, Brian Gloss, Gwenn Danet-Desnoyers,[...]. Mol Ther 2009
732
10

CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.
Theodoros Giavridis, Sjoukje J C van der Stegen, Justin Eyquem, Mohamad Hamieh, Alessandra Piersigilli, Michel Sadelain. Nat Med 2018
500
10

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
David L Porter, Bruce L Levine, Michael Kalos, Adam Bagg, Carl H June. N Engl J Med 2011
10

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.
Renier J Brentjens, Marco L Davila, Isabelle Riviere, Jae Park, Xiuyan Wang, Lindsay G Cowell, Shirley Bartido, Jolanta Stefanski, Clare Taylor, Malgorzata Olszewska,[...]. Sci Transl Med 2013
10

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Marco L Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park, Kevin Curran, Stephen S Chung, Jolanta Stefanski, Oriana Borquez-Ojeda, Malgorzata Olszewska,[...]. Sci Transl Med 2014
10

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Nirali N Shah, Steven L Highfill, Haneen Shalabi, Bonnie Yates, Jianjian Jin, Pamela L Wolters, Amanda Ombrello, Seth M Steinberg, Staci Martin, Cindy Delbrook,[...]. J Clin Oncol 2020
120
10

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, Joan Blade, Giampaolo Merlini, María-Victoria Mateos, Shaji Kumar, Jens Hillengass, Efstathios Kastritis, Paul Richardson,[...]. Lancet Oncol 2014
10

BCMA is essential for the survival of long-lived bone marrow plasma cells.
Brian P O'Connor, Vanitha S Raman, Loren D Erickson, W James Cook, Lehn K Weaver, Cory Ahonen, Ling-Li Lin, George T Mantchev, Richard J Bram, Randolph J Noelle. J Exp Med 2004
685
9

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.
Margherita Norelli, Barbara Camisa, Giulia Barbiera, Laura Falcone, Ayurzana Purevdorj, Marco Genua, Francesca Sanvito, Maurilio Ponzoni, Claudio Doglioni, Patrizia Cristofori,[...]. Nat Med 2018
585
9

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Cameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins, Colette Chaney, Sindhu Cherian, Xueyan Chen,[...]. Sci Transl Med 2016
589
9

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, Juliane Gust, W Conrad Liles, Mark M Wurfel, José A López, Junmei Chen, Dominic Chung, Susanna Harju-Baker,[...]. Blood 2017
479
9

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
Juliane Gust, Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, David Myerson, Luis F Gonzalez-Cuyar, Cecilia Yeung, W Conrad Liles, Mark Wurfel, Jose A Lopez,[...]. Cancer Discov 2017
597
9

Chimeric Antigen Receptor Therapy.
Carl H June, Michel Sadelain. N Engl J Med 2018
790
9

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
Justin Eyquem, Jorge Mansilla-Soto, Theodoros Giavridis, Sjoukje J C van der Stegen, Mohamad Hamieh, Kristen M Cunanan, Ashlesha Odak, Mithat Gönen, Michel Sadelain. Nature 2017
774
9

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Peter M Voorhees, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J Costa, Larry D Anderson,[...]. Blood 2020
170
9

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Di Wang, Jue Wang, Guang Hu, Wen Wang, Yi Xiao, Haodong Cai, Lijun Jiang, Li Meng, Yongkun Yang, Xiaoxi Zhou,[...]. Blood 2021
29
31

γ-Secretase directly sheds the survival receptor BCMA from plasma cells.
Sarah A Laurent, Franziska S Hoffmann, Peer-Hendrik Kuhn, Qingyu Cheng, Yuanyuan Chu, Marc Schmidt-Supprian, Stefanie M Hauck, Elisabeth Schuh, Markus Krumbholz, Heike Rübsamen,[...]. Nat Commun 2015
160
8

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Cameron J Turtle, Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, Sindhu Cherian, Xueyan Chen, Brent Wood, Arletta Lozanski, John C Byrd, Shelly Heimfeld,[...]. J Clin Oncol 2017
373
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.